

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Medizone International, Inc.

701 Ann Street, #564,
Stroudsburg, Pa 18360
646-383-0883

Harry Zhang <hzmails@yahoo.com>
SIC 5122

Annual Report **For the Period Ending: December 31, 2020** **(the "Reporting Period")**

As of December 31, 2020, the number of shares outstanding of our Common Stock was:

415,191,788

As of September 30, 2020, the number of shares outstanding of our Common Stock was:

415,191,788

As of December 31, 2019, the number of shares outstanding of our Common Stock was:

415,191,788

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Medizone International, Inc
Formerly Madison Funding, Inc. to 3-86

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Entity was formed in Nevada on 08/27/1984. Continued into Wyoming on April 27, 2021

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

701 Ann Street, #564,
Stroudsburg, Pa 18360
646-383-0883

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

On May 8, 2018, Medizone International, Inc., a Nevada corporation, commenced a voluntary bankruptcy proceeding under Chapter 7 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada. On May 10, 2021 Bankruptcy case 18-12662-ABL was fully discharged.
On July 14, 2020 a judgement was ordered and Medizone was appointed a Receiver, Angela Collette. Case number 2020-1064-CB

2) Security Information

Trading symbol:	<u>MZEIQ</u>	
Exact title and class of securities outstanding:	<u>Common</u>	
CUSIP:	<u>585013105</u>	
Par or stated value:	<u>.001</u>	
Total shares authorized:	<u>500,000,000</u>	as of date: <u>December 31, 2020</u>
Total shares outstanding:	<u>415,191,788</u>	as of date: <u>December 31, 2020</u>
Number of shares in the Public Float ² :	<u>290,626,708</u>	as of date: <u>December 31, 2020</u>
Total number of shareholders of record:	<u>2,247</u>	as of date: <u>December 31, 2020</u>

All additional class(es) of publicly traded securities (if any):

Trading symbol:	_____	
Exact title and class of securities outstanding:	<u>Preferred</u>	
CUSIP:	_____	
Par or stated value:	<u>.00001</u>	
Total shares authorized:	<u>50,000,000</u>	as of date: <u>December 31, 2020</u>
Total shares outstanding:	_____	as of date: <u>December 31, 2020</u>

Transfer Agent

Name: American Stock Transfer
Phone: (800) 937-5449
Email: chall@astfinancial.com
Address: 6201 15th Ave
Brooklyn, NY 11219-5411

Is the Transfer Agent registered under the Exchange Act?³ Yes: No:

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12.31.18</u> Common: <u>415,191,788</u> Preferred: 0			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
_____	_____	_____	_____	_____	_____	_____	_____	_____	
_____	_____	_____	_____	_____	_____	_____	_____	_____	
_____	_____	_____	_____	_____	_____	_____	_____	_____	
Shares Outstanding on Date of This Report: <u>Ending Balance</u> <u>Ending Balance:</u> Date <u>12.31.20</u> Common: <u>415,191,788</u> Preferred: 0									

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
 IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Caren Currier
Title: Consultant
Relationship to Issuer: Consultant

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- D. Statement of income;
- E. Statement of cash flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

None

- B. Please list any subsidiaries, parents, or affiliated companies.

None

- C. Describe the issuers' principal products or services.

Medizone's primary product is AsepticSure, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness..

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

None

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or**

controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Haining Zhang</u>	<u>Officer</u>	<u>Stroudsburg, PA</u>	<u>19,830,000,000</u>	<u>Common</u>	_____	<u>Shares are authorized during May 14, 2021 shareholders meeting</u>
<u>Angela Collette</u>	<u>Officer</u>	<u>Stroudsburg, PA</u>	<u>450,000,000</u>	<u>Common</u>	_____	<u>Shares are authorized during May 14, 2021 shareholders meeting</u>
_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: TBD
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Accountant or Auditor

Name: Caren Currier
Firm: _____
Address 1: 2313 Hollyhill Lane
Address 2: Denton, TX 76205
Phone: 626.429.2780
Email: carenlarsen@hotmail.com

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____

Phone:
Email:

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Haining Zhang certify that:

1. I have reviewed this Annual Disclosure Statements of Medizone International, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

June 12, 2021 [Date]

/s/Haining Zhang [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Haining Zhang certify that:

1. I have reviewed this Annual Disclosure Statements of Medizone International, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

June 12, 2021 [Date]

/s/Haining Zhang [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

MEDIZONE INTERNATIONAL, INC.
Balance Sheet Prev Year Comparison
As of December 31, 2020

	Dec 31, 20	Dec 31, 19	\$ Change	% Change
ASSETS				
Current Assets				
Checking/Savings				
Cash	0.00	0.00	0.00	0.0%
Total Checking/Savings	0.00	0.00	0.00	0.0%
Accounts Receivable	0.00	0.00	0.00	0.0%
Other Current Assets				
Inventory	0.00	0.00	0.00	0.0%
Lease Deposit	0.00	0.00	0.00	0.0%
Prepaid Expenses	0.00	0.00	0.00	0.0%
Trademark and Patents	0.00	0.00	0.00	0.0%
Total Other Current Assets	0.00	0.00	0.00	0.0%
Total Current Assets	0.00	0.00	0.00	0.0%
Fixed Assets				
Accumulated Depreciation	0.00	0.00	0.00	0.0%
Furniture and Equipment	0.00	0.00	0.00	0.0%
Total Fixed Assets	0.00	0.00	0.00	0.0%
Other Assets	0.00	0.00	0.00	0.0%
TOTAL ASSETS	0.00	0.00	0.00	0.0%
LIABILITIES & EQUITY				
Liabilities				
Current Liabilities				
Accounts Payable				
Accounts Payable	0.00	0.00	0.00	0.0%
Total Accounts Payable	0.00	0.00	0.00	0.0%
Credit Cards	0.00	0.00	0.00	0.0%
Other Current Liabilities				
Accrued Expenses	0.00	0.00	0.00	0.0%
Notes Payable	0.00	0.00	0.00	0.0%
Other Payables	0.00	0.00	0.00	0.0%
Payroll Liabilities	0.00	0.00	0.00	0.0%
Warranty Liability	0.00	0.00	0.00	0.0%
Total Other Current Liabil...	0.00	0.00	0.00	0.0%
Total Current Liabilities	0.00	0.00	0.00	0.0%
Long Term Liabilities	0.00	0.00	0.00	0.0%
Total Liabilities	0.00	0.00	0.00	0.0%

MEDIZONE INTERNATIONAL, INC.
Balance Sheet Prev Year Comparison
As of December 31, 2020

	Dec 31, 20	Dec 31, 19	\$ Change	% Change
Equity				
Additional Paid in Capital	35,185,874.00	35,185,874.00	0.00	0.0%
Capital Stock	0.00	0.00	0.00	0.0%
Common Stock	415,192.00	415,192.00	0.00	0.0%
Dividends Paid	0.00	0.00	0.00	0.0%
Opening Balance Equity	0.00	0.00	0.00	0.0%
Preferred Stock	0.00	0.00	0.00	0.0%
Retained Earnings	-35601066.00	-35601066.00	0.00	0.0%
Net Income	0.00	0.00	0.00	0.0%
Total Equity	0.00	0.00	0.00	0.0%
TOTAL LIABILITIES & EQUITY	0.00	0.00	0.00	0.0%

MEDIZONE INTERNATIONAL, INC.
Profit & Loss Prev Year Comparison
October through December 2020

	Oct - Dec ...	Oct - Dec ...	\$ Change	% Change
Ordinary Income/Expense				
Income				
Sales	0.00	0.00	0.00	0.0%
Total Income	0.00	0.00	0.00	0.0%
Expense				
Advertising and Promotion	0.00	0.00	0.00	0.0%
Automobile Expense	0.00	0.00	0.00	0.0%
Bank Service Charges	0.00	0.00	0.00	0.0%
Computer and Internet Expen...	0.00	0.00	0.00	0.0%
Depreciation Expense	0.00	0.00	0.00	0.0%
Insurance Expense	0.00	0.00	0.00	0.0%
Interest Expense	0.00	0.00	0.00	0.0%
Meals and Entertainment	0.00	0.00	0.00	0.0%
Office Supplies	0.00	0.00	0.00	0.0%
Payroll Expenses	0.00	0.00	0.00	0.0%
Professional Fees	0.00	0.00	0.00	0.0%
Rent Expense	0.00	0.00	0.00	0.0%
Repairs and Maintenance	0.00	0.00	0.00	0.0%
Telephone Expense	0.00	0.00	0.00	0.0%
Travel Expense	0.00	0.00	0.00	0.0%
Utilities	0.00	0.00	0.00	0.0%
Total Expense	0.00	0.00	0.00	0.0%
Net Ordinary Income	0.00	0.00	0.00	0.0%
Other Income/Expense				
Other Income	0.00	0.00	0.00	0.0%
Other Expense				
Ask My Accountant	0.00	0.00	0.00	0.0%
Total Other Expense	0.00	0.00	0.00	0.0%
Net Other Income	0.00	0.00	0.00	0.0%
Net Income	0.00	0.00	0.00	0.0%

MEDIZONE INTERNATIONAL, INC.
Profit & Loss Prev Year Comparison
January through December 2020

	Jan - Dec 20	Jan - Dec 19	\$ Change	% Change
Ordinary Income/Expense				
Income				
Sales	0.00	0.00	0.00	0.0%
Total Income	0.00	0.00	0.00	0.0%
Expense				
Advertising and Promotion	0.00	0.00	0.00	0.0%
Automobile Expense	0.00	0.00	0.00	0.0%
Bank Service Charges	0.00	0.00	0.00	0.0%
Computer and Internet Expen...	0.00	0.00	0.00	0.0%
Depreciation Expense	0.00	0.00	0.00	0.0%
Dues & Subscriptions	0.00	0.00	0.00	0.0%
Insurance Expense	0.00	0.00	0.00	0.0%
Interest Expense	0.00	0.00	0.00	0.0%
Meals and Entertainment	0.00	0.00	0.00	0.0%
Office Supplies	0.00	0.00	0.00	0.0%
Payroll Expenses	0.00	0.00	0.00	0.0%
Professional Fees	0.00	0.00	0.00	0.0%
Rent Expense	0.00	0.00	0.00	0.0%
Repairs and Maintenance	0.00	0.00	0.00	0.0%
Stock Issued in Lieu of Comp	0.00	0.00	0.00	0.0%
Telephone Expense	0.00	0.00	0.00	0.0%
Travel Expense	0.00	0.00	0.00	0.0%
Utilities	0.00	0.00	0.00	0.0%
Total Expense	0.00	0.00	0.00	0.0%
Net Ordinary Income	0.00	0.00	0.00	0.0%
Other Income/Expense				
Other Income	0.00	0.00	0.00	0.0%
Other Expense				
Ask My Accountant	0.00	0.00	0.00	0.0%
Total Other Expense	0.00	0.00	0.00	0.0%
Net Other Income	0.00	0.00	0.00	0.0%
Net Income	0.00	0.00	0.00	0.0%

MEDIZONE INTERNATIONAL, INC.**Statement of Cash Flows**October through December 2020

	<u>Oct - Dec 20</u>
OPERATING ACTIVITIES	
Net Income	0.00
Adjustments to reconcile Net Income to net cash provided by operations:	
Inventory	0.00
Lease Deposit	0.00
Prepaid Expenses	0.00
Trademark and Patents	0.00
Accounts Payable	0.00
Accrued Expenses	0.00
Notes Payable	0.00
Other Payables	0.00
Payroll Liabilities	0.00
Warranty Liability	0.00
Net cash provided by Operating Activities	<u>0.00</u>
INVESTING ACTIVITIES	
Accumulated Depreciation	0.00
Furniture and Equipment	0.00
Net cash provided by Investing Activities	<u>0.00</u>
FINANCING ACTIVITIES	
Additional Paid in Capital	0.00
Capital Stock	0.00
Common Stock	0.00
Dividends Paid	0.00
Opening Balance Equity	0.00
Preferred Stock	0.00
Retained Earnings	0.00
Net cash provided by Financing Activities	<u>0.00</u>
Net cash increase for period	0.00
Cash at beginning of period	<u>0.00</u>
Cash at end of period	<u><u>0.00</u></u>

MEDIZONE INTERNATIONAL, INC.

Statement of Cash Flows

January through December 2020

	<u>Jan - Dec 20</u>
OPERATING ACTIVITIES	
Net Income	0.00
Adjustments to reconcile Net Income to net cash provided by operations:	
Inventory	0.00
Lease Deposit	0.00
Prepaid Expenses	0.00
Trademark and Patents	0.00
Accounts Payable	0.00
Accrued Expenses	0.00
Due to Related Party - Harry	0.00
Notes Payable	0.00
Other Payables	0.00
Payroll Liabilities	0.00
Warranty Liability	0.00
Net cash provided by Operating Activities	0.00
INVESTING ACTIVITIES	
Accumulated Depreciation	0.00
Furniture and Equipment	0.00
Net cash provided by Investing Activities	0.00
FINANCING ACTIVITIES	
Additional Paid in Capital	0.00
Capital Stock	0.00
Common Stock	0.00
Dividends Paid	0.00
Opening Balance Equity	0.00
Preferred Stock	0.00
Retained Earnings	0.00
Net cash provided by Financing Activities	0.00
Net cash increase for period	0.00
Cash at beginning of period	0.00
Cash at end of period	<u><u>0.00</u></u>

Medizone International
Shareholders' Equity (Deficiency)
(Unaudited)

	Common Stock		Preferred Stock		Add'l Paid in Capital	Accumulated Deficit	Total Stockholders' Equity/(Deficit)
	Shares	Amount	Shares	Amount			
Balance, December 31, 2017	415,191,788	415,192	-	-	35,185,874	(35,601,066)	-
Shares Issued Net Gain/(loss) for year ended December 31, 2018	415,191,788	415,192	-	-	35,185,874	(35,601,066)	-
Balance December 31, 2018	415,191,788	415,192	-	-	35,185,874	(35,601,066)	-
Shares Issued Net Gain/(loss) for year ended December 31, 2019	415,191,788	415,192	-	-	35,185,874	(35,601,066)	-
Balance December 31, 2019	415,191,788	415,192	-	-	35,185,874	(35,601,066)	-
Shares Issued Net Gain/(loss) for year ended December 31, 2020	415,191,788	415,192	-	-	35,185,874	(35,601,066)	-
Balance December 31, 2020	415,191,788	415,192	-	-	35,185,874	(35,601,066)	-

MEDIZONE INTERNATIONAL, INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
For The
Period Ended December 31, 2020

NOTE 1: THE COMPANY AND THE SIGNIFICANT ACCOUNTING POLICIES

The Company

Medizone's primary product is AsepticSure, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness.

Basis of presentation

The unaudited consolidated financial statements of the Company have been prepared in accordance with the U.S. Generally Accepted Accounting Principles ("U.S. GAAP").

NOTE 2: STOCKHOLDERS EQUITY

As of December 31, 2020, and December 31, 2019, the Issuer's outstanding and authorized common shares and shareholders were approximately as follows:

- (i) December 31, 2020
- (ii) 500,000,000 shares of common stock authorized
- (iii) 415,191,788 shares of common stock outstanding
- (iv) 290,626,708 common shares were free trading;
- (i) December 31, 2019
- (ii) 500,000,000 shares of common stock authorized
- (iii) 415,191,788 shares of common stock outstanding
- (iv) 290,626,708 common shares were free trading;

Item 3 Cash and Cash Equivalents

Due to no current operations, there has been no change in our cash or cash equivalents

Item 4 Management's Discussion and Analysis or Plan of Operation.

Management's Discussion and Analysis of Financial Condition and Results of Operations, which we refer to as MD&A, is intended to help the reader understand Medizone International, Inc., our operations and our present business environment. MD&A is

provided as a supplement to, and should be read in conjunction with, our financial statements and the accompanying notes for the period ended December 31, 2020.

Business Overview

Medizone's primary product is AsepticSure, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness.

Item 5 Legal Proceedings.

None

Item 6 Defaults on Senior Securities.

None.

Item 7 Other Information.

None.

Item 8 Subsequent Events.

Transferred Domicile from Nevada to Wyoming on April 27, 2021

Common Shares increased to 50,000,000,000 upon transfer to Wyoming on April 27, 2021

Common Shares are authorized during May 14, 2021 shareholders meeting

Haining Zhang	19,830,000,000
Angela Collette	450,000,000